Zero Candida Technologies Inc. · TSXV:ZCT
Zero Candida Technologies — Investor Presentation (July 2025)
10 slides from Zero Candida Technologies's investor presentation, July 2025
Slide 1: Revolutionizing Women's Health Through Ground-Breaking Technology
Revolutionizing Women's Health Through Ground-Breaking Technology July 2025 TSXV: ZCT OTCQB: ZCTFF FSE: 9L2
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements based on expectations, forecasts, and assumptions about future events or performance. These statements can be identified by terms such as “will,” “may,” “estimate,” “expect,” “plan,” “project,” “intend,” “anticipate,” o
Slide 3: ZCT Overview
ZCT OVERVIEW FemTech company developing the first AI-enabled intravaginal therapeutic device for treating vulvovaginal candidiasis (VVC), commonly known as yeast infections. The technology combines blue light therapy, targeted drug delivery, and wireless diagnostics for real time data transmission t
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS 03 04 05 $15.6B global antifungal • Blue light therapy + FDA De Novo 99.999% Candida Funded for clinical trials market gel + AI diagnostics classification underway eradication in <3 hours Opportunity to leverage Non-drug, non- Device confirmed 100% $22.1B women’s health Pursuin
Slide 5: The VVC Landscape
THE VVC LANDSCAPE 100-200M Recurrent (4+) VVC cases each year In Billion USD 75% VVC Treatment of women will have Market VVC at least once ~ US$2.04B FemTech Age 24-34 Market Highest prevalence and growing ~ US$115B 5 TSXV: ZCT | OTCQB: ZCTFF | FSE: 9L2
Slide 6: The Problem
THE PROBLEM Until recently, the root cause of VVC was poorly understood and inadequately addressed by existing medication: 1) Vaginal Ovules 2) Oral Drugs 3) Creams Leading to therapeutic failures... Microbial Resistence Lack of Drug Efficacy Host Susceptibilities REDUCTION IN THE ALTERATION IN THE
Slide 7: The Technology
THE TECHNOLOGY No side effects or chemicals, frequent doctor visits or perscriptions. A non-drug blue light therapy in a SMART vaginal diagnostic device. Offering precise and personalized treatment, with individualized light frequency targeting, to produce 99.999% fungal eradication in only 3 hours.
Slide 8: The Solution
THE SOLUTION ZC-01 DEVICE THERAPEUTIC BLUE LIGHT AT PRECISE WAVELENGTH AND INTENSITY GEL-BASED CLOTRIMAZOLE DELIVERY SYSTEM ARTIFICIAL INTELLIGENCE WI-FI AND VOIP CONNECTIVITY TEMPERATURE AND PH SENSORS DISCREET AND PATIENT-CENTRIC DESIGN 67 TSXV: ZCT | OTCQB: ZCTFF| FSE: 9L2
Slide 9: Upcoming Milestones / Capital Structure
UPCOMING MILESTONES CAPITAL STRUCTURE SHARE PRICE (TSXV) MARKET CAP (CAD) SHARES OUTSTANDING FULLY DILUTED SHARES INSIDER OWNERSHIP 8 TSXV: ZCT | OTCQB: ZCTFF | FSE: 9L2
Slide 10: Thank You!
OTCQB: ZCTFF TSXV: ZCT FSE: 9L2 THANK YOU! investors@zero-candida.com +1 (647) 874 3767 zero-candida.com
Zero Candida Technologies — Investor Presentation (July 2025) on 6ix